| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c18e47d9693c78da88d2b1293d3a8ad6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-827 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6432
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
1993-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2000-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_629c75525a1a0153ab245c9d0832a8f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99768833cbdadd39fd2e473761f4fa39 |
| publicationDate |
2000-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0631501-B1 |
| titleOfInvention |
Glycosylation-mediated inhibition of factor x |
| abstract |
Reagents that specifically bind a carbohydrate target wherein sialic acid is linked at the nonreducing terminus of a glycoside to a galactose or galactosamine residue through an alpha 2-6 linkage are able to inhibit the conversion of human Factor X to human Factor Xa. These reagents (SA/Gal/GalNAc binding reagents) as well as other strategies for inhibiting the conversion of Factor X to Factor Xa are useful in treating thrombosis, inflammation and other conditions associated with excess thrombin activity. |
| priorityDate |
1992-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |